FDA Approves Cobenfy: A Breakthrough Antipsychotic with New Mechanism for Schizophrenia Treatment

The FDA has approved Cobenfy (xanomeline and trospium chloride) for treating schizophrenia in adults, marking a breakthrough as the first antipsychotic to target cholinergic receptors instead of dopamine receptors. Schizophrenia, a chronic mental illness affecting about 1% of Americans, causes psychotic symptoms and cognitive difficulties, and is a leading cause of disability globally. Cobenfy’s efficacy was demonstrated in two 5-week clinical trials where participants saw a significant reduction in symptoms. However, it carries warnings for potential side effects, including urinary retention, liver and kidney issues, and is not recommended for patients with certain pre-existing conditions.

Source: https://www.fda.gov/news-events/press-announcements/fda-approves-drug-new-mechanism-action-treatment-schizophrenia